SAVA Historical PE Ratio Notes

— Cassava Sciences (ticker symbol SAVA) is a clinical-stage biotechnology company focused primarily on developing novel treatments for Alzheimer’s disease. Its flagship drug candidate, simufilam, is designed to improve cognition and slow disease progression in patients. As SAVA is still in the research & development phase with no approved therapies on the market, its revenues have historically been minimal, relying largely on grants & investor funding to support ongoing clinical trials. This is crucial when examining SAVA’s historical price-to-earnings (PE) ratio: for a company like SAVA, most periods will show a negative or undefined PE ratio due to consistent net losses rather than profits. Occasionally, market speculation around clinical trial progress or regulatory milestones has caused sharp price movements, affecting the stock's price but not significantly altering the earnings profile, thus leading to highly volatile or meaningless PE ratios. When reviewing SAVA’s historical PE data, remember that these numbers reflect the high risk & uncertainty inherent in pre-revenue biotech stocks, and traditional valuation metrics like the PE ratio may not provide meaningful guidance until — and if — Cassava achieves commercial success.

On this page we presented the SAVA Historical PE Ratio information for Cassava Sciences' stock. The average SAVA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 25.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average SAVA historical PE based on this TTM earnings result method is 0.9. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this SAVA historical PE result, against the recent PE: when this page was posted on 3/10/2026, the most recent closing price for SAVA had been 2.38, and the most recent quarterly earnings result, annualized, was 0.52. Meanwhile, the most recent TTM earnings summed to 3.43. From these numbers, we calculate the recent SAVA PE on 3/10/2026 based on annualized quarterly EPS was 4.6. Based on SAVA's history, that recent PE is low relative to the historical average, with the recent PE 81.7% lower than the historical average PE across our data set for Cassava Sciences. Looking at the recent SAVA PE on 3/10/2026 based on TTM EPS, we calculate the ratio at 0.7. Based on SAVA's history, that recent PE is low relative to the historical average, with the recent PE 22.2% lower than the average PE across our Cassava Sciences data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on SAVA or any other given stock, valuation analysis for SAVA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Cassava Sciences PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SAVA. Thanks for visiting, and the next time you need to research SAVA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.